Quotables
"Radio has no future."
Lord Kelvin, British mathematician and physicist ; 1897
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7273857 | Benzimidazolidinone derivatives as muscarinic agents Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the s... | 09/25/2007 |
| 7271154 | Antibiotic conjugates This invention features a compound of the following formula: wherein T is a transportophore, L is a bond or linker, and C is an antibiotic therapeutic agent, the transportophore is covalently bonded to the antibi... | 09/18/2007 |
| 7271160 | Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases Bifunctional molecules comprising two hsp-binding moieties which bind to hsp90 in the pocket to which ansamycin antibiotics bind connected via a linker are effective for inducing the degradation and/or inhibition of HER-family tyrosine kinases. For example, a... | 09/18/2007 |
| 7271164 | Cyclohepta[b][1,4]diazepino[6,7,1,-hi]indoles and derivatives This invention provides compounds of the formula: wherein R1 and R2 are each, independently, H, alkyl, cycloalkyl, —CH2-cycloalkyl, alkoxy, halogen, fluorinated alkyl, —CN, â€... | 09/18/2007 |
| 7271163 | Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives This invention provides compounds of the formulae: wherein: R1 is hydrogen, —C(O)CH3 or alkyl of 1-6 carbon atoms; R2 and R | 09/18/2007 |
| 7271162 | Cycloocta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives This invention provides compounds of formula I having the structure wherein: R1 and R2 are H, alkyl, cycloalkyl, alkoxy, halogen, fluorinated alkyl, —CN, —NH—SO2-alkyl, —S... | 09/18/2007 |
| 7268230 | Quinazoline compounds The invention relates to compounds of the formula (I): wherein ring C is as defined herein, for example indolyl, indazolyl or azaindolyl; Z is —O—, —NH— or —S—; n is 0-5; m is 0-3; R1 and R2 are defined herein including groups: (i) ... | 09/11/2007 |
| 7268134 | Medical devices employing triazine compounds and compositions thereof The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced... | 09/11/2007 |
| 7267971 | Process for preparation of thermostable enzyme A process for the preparation of thermostable enzyme glucose oxidase of high Transition temperature (Tm) useful for biological processes of high temperature, said process comprising steps of silanizaton of the activated glass beads by evaporative depositi... | 09/11/2007 |
| 7265114 | Methods and compositions of novel triazine compounds The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced... | 09/04/2007 |
| 7262215 | N-carbacycle monosubstituted indolocarbazoles as protein kinase inhibitors This invention relates to N-carbacycle monosubstituted indolocarbazole compounds. Furthermore, this invention relates to medicaments comprising N-carbacycle monosubstituted indolocarbazoles compounds and the use of such compounds for treating non-insulin dependent d... | 08/28/2007 |
| 7259156 | Geldanamycin compounds and method of use Geldanamycin compounds having a structure according to formula I where Q1, L, L1, R5, R6, and R11 are as defined herein, are useful for treating a disease or... | 08/21/2007 |
| 7256215 | Crystals of 5-hydroxycarbamimidoyl-2-hydroxybenzenesulfonamide derivative The present invention provides a novel crystalline form of n-butyl[4-[2-[2-hydroxy-5-(N-hydroxycarbamimidoyl) benzenesulfonylamino]ethyl]-2′-methanesulfonyl-3-yloxy] acetate hydrochloride, pharmaceutical compositions containing the same and their uses, which exhib... | 08/14/2007 |
| 7256286 | Bryostatin analogues, synthetic methods and uses Biologically active compounds related to the bryostatin family of compounds, having simplified spacer domains and/or improved recognition domains are disclosed, including methods of preparing and utilizing the same. ... | 08/14/2007 |
| 7253211 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for ... | 08/07/2007 |
| 7250157 | Dermatological compositions and methods Disclosed are methods and compositions for regulating the melanin content of mammalian melanocytes; regulating pigmentation in mammalian skin, hair, wool or fur; treating or preventing various skin and proliferative disorders; by administration of various compounds,... | 07/31/2007 |
| 7250440 | (Hydroxyphenyl)-1H-indole-3-carbaldehyde oxime derivatives as estrogenic agents This invention provides estrogen receptor modulators of formula I, having the structure where R1, R2, R3, and R4 are as defined in the specification, or a pharmaceutica... | 07/31/2007 |
| 7244711 | Association of calpain inhibitors and reactive oxygen species trapping agents The invention concerns a pharmaceutical composition comprising, as active principle, at least a calpain inhibiting substance and at least a substance trapping reactive oxygen species (ROS), and optionally an acceptable pharmaceutical carrier. The invention also conc... | 07/17/2007 |
| 7244747 | Imidazole derivatives, processes for preparing them and their uses The present invention relates to imidazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. ... | 07/17/2007 |
| 7244594 | Microbial transformation method for the preparation of an epothilone A microbial method for the preparation of an epothilone containing a terminal hydroxyalkyl group, comprising contacting at least one epothilone having a terminal alkyl group with an enzyme or microorganism capable of catalyzing the selective hydroxylation of said al... | 07/17/2007 |
| 7244703 | Pharmaceutical compositions and methods for peptide treatment Compositions and methods for treating a patient with a pharmaceutically active peptide that combines a pharmaceutically active peptide, a permeation enhancer, and a carrier, are disclosed. ... | 07/17/2007 |
| 7241755 | Epothilone derivatives The present invention relates to compounds of the formula in which the variables G, W, Q, X, Y, B1, B2, Z1, Z2, and R1–R7 are as defined herein,... | 07/10/2007 |
| 7241754 | 2-Desmethyl ansamycin compounds 2-Desmethyl ansamycins having a structure according to formula I, where R1, R2, R3, R4, R5 and R6 are as defined herein, and other 2-desmethyl ansamycins are useful as antiproliferative agents ... | 07/10/2007 |
| 7241773 | 3-quinuclidinyl heteroatom bridged biaryl derivatives Compounds of formula: or pharmaceutically acceptable salts, esters, amides, or prodrugs thereof, wherein: A and G are each independently N or N+—O−; m and n are each independently 0, 1, ... | 07/10/2007 |
| 7238712 | Indole-type derivatives as inhibitors of p38 kinase The invention is directed to methods to inhibit p38-α kinase using compounds of the formula and the pharmaceutically acceptable salts thereof, or a pharmaceutical composition thereof, wh... | 07/03/2007 |
| 7238715 | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists A method of treating a patient suffering from pancreatitis comprising treating said patient with a therapeutically effective amount of a cholinergic agonist selective for an α7 nicotinic receptor in an amount sufficient to decrease the amount of the proinflammatory... | 07/03/2007 |
| 7238682 | Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases Bifunctional molecules comprising two hsp-binding moieties which bind to hsp90 in the pocket to which ansamycin antibiotics bind connected via a linker are effective for inducing the degradation and/or inhibition of HER-family tyrosine kinases. For example, a compou... | 07/03/2007 |
| 7235542 | Diagnosis and treatment of human kidney diseases Kidney disease is diagnosed by measuring urinary catalytic iron in humans. Progressive kidney disease is treated by administering an iron chelator to humans. In particular, the progression of kidney disease essentially can be halted and the severity of kidney diseas... | 06/26/2007 |
| 7235541 | Neurokinin antagonists for use as medicaments The present application relates to internally cyclized naphthamide compounds of the formula Ia (wherein R1a, R1b, R1c, R2, R3, R4, R5, R6, R7, R8, X1 | 06/26/2007 |
| 7232811 | Furosemide modulators of HM74 Host cells expressing HM74 were used to obtain furosemide-like molecules with agonist activity having the following structure formula: ... | 06/19/2007 |
| 7232822 | Reverse-turn mimetics and method relating thereto Conformationally constrained compounds that mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins are disclosed. Such reverse-turn mimetic structures have utility over a wide range of fields, including use as diagnostic a... | 06/19/2007 |
| 7232824 | Quinazoline derivatives as medicaments Quinazoline derivatives have the formula: or the pharmaceutically acceptable salts thereof; wherein each of Z5, Z6, Z7 and Z8 ... | 06/19/2007 |
| 7232840 | Agents for combating plant pests The present invention relates to compositions for controlling plant pests containing the compound of formula (I) in a mixture with fungicidally active compounds, except for cyclopropylcarboxamide derivatives and ... | 06/19/2007 |
| 7229986 | Melanin-concentrating hormone antagonist A melanin-concentrating hormone antagonist comprising a compound of the formula: wherein R is hydrogen atom or a cyclic group which may be substituted; X is a bond or a spacer having a main chain of 1 to 10 atoms... | 06/12/2007 |
| 7229981 | Process for the preparation of aminoalcohol derivatives and their further conversion to (1R,4S)-4-(2-amino-6-chloro-5-formamido-4-pyrimidinyl)-amino)-2-cyclopentenyl-1-methanol The invention relates to a novel process for the preparation of an aminoalcohol of the formula racemically or optically active, starting from 2-azabi-cyclo[2.2.1]hept-5-en-3-one, its further conversion to give th... | 06/12/2007 |
| 7230000 | Methods and compositions utilizing quinazolinones Quinazolinones of formulae 1a, 1b, 1c and 1d are disclosed. They are useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity ... | 06/12/2007 |
| 7227043 | 2-phenyl-2-substituted-1,3-diketones The invention relates to novel phenyl-substituted cyclopentane- and cyclohexane-1,3-dione derivatives of the formula (I) in which W, X, Y, Z, A, B, Q1, Q2, Q3 | 06/05/2007 |
| 7226929 | Pyrrolidin-2-one derivatives as inhibitors of factor xa The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical con... | 06/05/2007 |
| 7227020 | Azaindoles Chemical compositions containing physiologically active compounds of general formula (I): wherein R1 is aryl or heteroaryl; R2 represents hydrogen, acyl, cyano, halo, lower alkenyl or lower ... | 06/05/2007 |
| 7227035 | Bis-aryl sulfonamides Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls i... | 06/05/2007 |
